Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 3/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 16/20 | 0.71 |
| ▸ | SLC6A2 | P23975 | 15/20 | 0.71 |
| ▸ | OPRM1 | P35372 | 11/20 | 0.71 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.71 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.71 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.71 |
| ▸ | HTR3A | P46098 | 2/20 | 0.48 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14532254 | 1.00 | SLC22A1 (1.00) | SLC22A1SLC6A4SLC6A2OPRM1OPRD1 | |
| SCHEMBL4393889 | 1.00 | SLC22A1 (1.00) | SLC22A1SLC6A4SLC6A2OPRM1OPRD1 | |
| SCHEMBL13942259 | 1.00 | SLC22A1 (1.00) | SLC22A1SLC6A4SLC6A2OPRM1OPRD1 | |
| SCHEMBL4393890 | 1.00 | SLC22A1 (1.00) | SLC22A1SLC6A4SLC6A2OPRM1OPRD1 | |
| SCHEMBL11154779 | 0.87 | SLC22A1 (0.76) | SLC22A1SLC6A4SLC6A2OPRM1OPRD1 | |
| SCHEMBL14538756 | 0.86 | SLC6A4 (0.76) | SLC22A1SLC6A4SLC6A2OPRM1OPRD1 | |
| SCHEMBL19021691 | 0.85 | SLC22A1 (0.74) | SLC22A1SLC6A4SLC6A2OPRM1OPRD1 | |
| SCHEMBL5411927 | 0.85 | SLC6A4 (0.74) | SLC22A1SLC6A4SLC6A2OPRM1OPRD1 | |
| SCHEMBL220363 | 0.85 | SLC6A4 (0.74) | SLC22A1SLC6A4SLC6A2OPRM1OPRD1 | |
| SCHEMBL13007830 | 0.85 | SLC6A4 (0.74) | SLC22A1SLC6A4SLC6A2OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10416175-B2 | Opioid detection | RANDOX LABORATORIES LIMITED (GB) | 2019-09-17 | — | — | US | disclosed |
| EP-3185015-A1 | OPIOID DETECTION | Randox Laboratories Ltd. (GB) | 2017-06-28 | — | — | EP | disclosed |
| US-20170176476-A1 | Opioid Detection | NORTHERN BANK LIMITED (IE) | 2017-06-22 | — | — | US | disclosed |
| EP-1988398-B1 | Immunoassay for tramadol and its major metabolites | RANDOX LAB LTD (GB) | 2009-12-16 | — | — | EP | disclosed |
| WO-2009018169-A1 | SUBSTITUTED CYCLOHEXANOLS | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| EP-1988398-A1 | Immunoassay for tramadol and its major metabolites | Randox Laboratories Ltd. (GB) | 2008-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10416175-B2 | Opioid detection | OPRM1, OPRK1, OPRD1 | SLC22A1 3022/4885SLC6A4 432/4885SLC6A2 630/4885 |
| US-20170176476-A1 | Opioid Detection | OPRM1, OPRK1, OPRD1 | SLC22A1 3022/4885SLC6A4 432/4885SLC6A2 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.